A novel tropically stable oral amphotericin B formulation (iCo-010) exhibits efficacy against visceral leishmaniasis in a murine model

PLoS Neglected Tropical Diseases

Volumn 4, Issue 12, 2010, Pages 1-6

  Wasan, Ellen K ^a   Gershkovich, Pavel ^b   Zhao, Jinying ^b   Zhu, Xiaohua ^c   Werbovetz, Karl ^c   Tidwell, Richard R ^d   Clement, John G ^e   Thornton, Sheila J ^b   Wasan, Kishor M ^b  

^a BRITISH COLUMBIA INSTITUTE OF TECHNOLOGY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c OHIO STATE UNIVERSITY   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e ICo Therapeutics Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; DIACYLGLYCEROL; MONOACYLGLYCEROL; ANTIPROTOZOAL AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STABILITY; EMULSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTESTINE FLUID; LEISHMANIA DONOVANI; LIGHT SCATTERING; MEMBRANE PERMEABILITY; MOUSE; NONHUMAN; THERMOSTABILITY; VISCERAL LEISHMANIASIS; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; DISEASE MODEL; ORAL DRUG ADMINISTRATION; TEMPERATURE; TIME; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AMPHOTERICIN B; ANIMALS; ANTIPROTOZOAL AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DISEASE MODELS, ANIMAL; DRUG STABILITY; LEISHMANIASIS, VISCERAL; MICE; MICE, INBRED BALB C; TEMPERATURE; TIME FACTORS; TREATMENT OUTCOME;

EID: 78650690322     PISSN: None     EISSN: None     Source Type: Journal    
DOI: 10.1371/journal.pntd.0000913     Document Type: Article

References (10)

1. Chappuis F, Sundar S, Hailu A, Ghalib H, Rijal S, et al. (2007) Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat Rev Microbiol 5: 873-882.
2. Malla N, Mahajan RC (2006) Pathophysiology of visceral leishmaniasis - some recent concepts. Indian J Med Res 123: 267-274.
3. Singh RK, Pandey HP, Sundar S (2006) Visceral leishmaniasis (kala-azar): challenges ahead. Indian J Med Res 123: 331-344.
4. Wasan EK, Bartlett K, Gershkovich P, Sivak O, Banno B, et al. (2009) Development and characterization of oral lipid-based Amphotericin B formulations with enhanced drug solubility, stability and antifungal activity in rats infected with Aspergillus fumigatus or Candida albicans. Int J Pharm 372: 76-84.
5. Gershkovich P, Wasan EK, Lin M, Sivak O, Leon CG, et al. (2009) Pharmacokinetics and biodistribution of amphotericin B in rats following oral administration in a novel lipid-based formulation. J Antimicrob Chemother 64: 101-108.
6. Wasan KM, Wasan EK, Gershkovich P, Zhu X, Tidwell RR, et al. (2009) Highly Effective Oral Amphotericin B Formulation against Murine Visceral leishmaniasis. J Infect Dis 200: 357-360.
7. Gradoni L, Davidson RN, Orsini S, Betto P, Giambenedetti M (1993) Activity of liposomal amphotericin B (AmBisome) against Leishmania infantum and tissue distribution in mice. J Drug Target 1: 311-316.
8. Olivier M, Tanner CE (1987) Susceptibilities of macrophage populations to infection in vitro by Leishmania donovani. Infect Immun 55: 467-471.
9. Lim HJ, Parr MJ, Masin D, McIntosh NL, Madden TD, et al. (2000) Kupffer cells do not play a role in governing the efficacy of liposomal mitoxantrone used to treat a tumor model designed to assess drug delivery to liver. Clin Cancer Res 6: 4449-4460.
10. van Etten EW, Otte-Lambillion M, van Vianen Wten Kate MT, Bakker-Woudenberg AJ (1995) Biodistribution of liposomal amphotericin B (AmBisome) and amphotericin B-desoxycholate (Fungizone) in uninfected immunocompetent mice and leucopenic mice infected with Candida albicans. J Antimicrob Chemother 35: 509-519.